{"id":"NCT04170296","sponsor":"Endo Pharmaceuticals","briefTitle":"Real World CCH Study in Adult Females With Cellulite","officialTitle":"A Real World, Multicenter, Open-Label, Multiple Dose Study to Assess the Effectiveness of, and Satisfaction With, CCH Treatment of Buttocks or Thigh Cellulite in Adult Females","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-11-01","primaryCompletion":"2020-10-06","completion":"2021-01-08","firstPosted":"2019-11-20","resultsPosted":"2022-02-22","lastUpdate":"2022-02-22"},"enrollment":153,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Edematous Fibrosclerotic Panniculopathy (EFP)","Cellulite"],"interventions":[{"type":"DRUG","name":"EN3835","otherNames":[]}],"arms":[{"label":"Cohort 1: Posterolateral Thigh","type":"EXPERIMENTAL"},{"label":"Cohort 2: Buttocks","type":"EXPERIMENTAL"}],"summary":"This is a multicenter, open-label, multiple dose, 2 cohort, Phase 3b study to assess the safety and efficacy of CCH in adult women with mild or moderate edematous fibrosclerotic panniculopathy (EFP).\n\nCohort 1 will include approximately 80 subjects with mild or moderate EFP in the posterolateral thighs and Cohort 2 will include approximately 70 subjects with mild or moderate EFP in the buttocks.","primaryOutcome":{"measure":"The Proportion of Participants With Improved (+1 or Better) Score on I-GAIS for Either Posterolateral Thigh","timeFrame":"90 Days","effectByArm":[{"arm":"Cohort 1: Posterolateral Thigh","deltaMin":58,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":12,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":81},"commonTop":["Injection site bruising","Injection site pain","Injection site discolouration","Injection site swelling","Injection site pruritus"]}}